Imatinib mesylate, a tyrosine kinase inhibitor, is used for the treatment of chronic myeloid leukemia (CML), gastrointestinal stromal tumor (GIST), mastocytosis, myelodysplastic and myeloproliferative disorders. Cutaneous side effects of imatinib include xerosis, photosensitivity, pigmentary changes hypopigmentation and rarely hyperpigmentation. A 19-years-old male diagnosed case of CML currently on Imatinib 400mg once daily for 18 months presented with gradually progressive brownish discoloration of face since 6 months. Based on history, clinical features and a temporal association with drug intake, a diagnosis of imatinib-induced melasma-like pigmentation was made and the patient was started on sunscreen and topical depigmenting agents.